Randomized Phase II Trial of Osimertinib With or Without Local Consolidation Therapy (LCT) for Patients With EGFR-Mutant Metastatic NSCLC (NORTHSTAR)
Latest Information Update: 12 Jan 2024
Price :
$35 *
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NORTHSTAR
- 09 Jan 2024 Planned End Date changed from 1 Jan 2024 to 1 Jun 2025.
- 09 Jan 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jun 2025.
- 16 Feb 2023 Status changed from recruiting to active, no longer recruiting.